Aligos Therapeutics, Inc.
(NASDAQ : ALGS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.10%162.160.7%$1254.93m
PFEPfizer Inc. 2.47%38.530.9%$1060.23m
MRKMerck & Co., Inc. 1.03%77.450.7%$958.24m
ABBVAbbVie, Inc. 1.02%107.981.9%$778.70m
BMYBristol-Myers Squibb Co. 1.54%65.431.0%$758.06m
LLYEli Lilly & Co. 1.76%189.201.1%$575.67m
AZNAstraZeneca Plc -0.18%50.741.2%$463.76m
GSKGlaxoSmithKline Plc 0.21%37.770.2%$217.86m
NVSNovartis AG 0.95%88.030.2%$157.01m
RPRXRoyalty Pharma Plc 0.53%41.870.2%$143.72m
VTRSViatris, Inc. 0.90%13.400.0%$127.48m
CVACCureVac NV 5.04%109.290.0%$96.11m
RGENRepligen Corp. -0.13%213.306.8%$86.07m
NVONovo Nordisk A/S 0.95%72.190.1%$62.10m
SNYSanofi 1.20%51.300.2%$61.19m

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.